Association of valine and leucine at HLA-DRB1 position 11 with radiographic progression in rheumatoid arthritis, independent of the shared epitope alleles but not independent of anti-citrullinated protein antibodies

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 877-886

  Van Steenbergen, H W ^a   Raychaudhuri, S ^b,f,g   Rodriguez Rodriguez L ^c   Rantapaa Dahlqvist S ^d   Berglin, E ^d   Toes, R E M ^a   Huizinga, T W J ^a   Fernandez Gutierrez B ^c   Gregersen, P K ^e   Van Der Helm Van Mil, A H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; HLA DRB1 ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; VALINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; AGED; FOOT JOINT; GENE FREQUENCY; GENETICS; HAND JOINT; IMMUNOLOGY; MIDDLE AGED; RADIOGRAPHY;

ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EPITOPES; FEMALE; FOOT JOINTS; GENE FREQUENCY; HAND JOINTS; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 84925745502     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39018     Document Type: Article

References (27)

1. De Rooy DP, Zhernakova A, Tsonaka R, Willemze A, Kurreeman BA, Trynka G, et al. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 2014; 73: 1163-9.
2. Van der Helm-van Mil AH, Huizinga TW, Schreuder GM, Breedveld FC, de Vries RR, Toes RE,. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum 2005; 52: 2637-44.
3. Van der Woude D, Lie BA, Lundstrom E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1 1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010; 62: 1236-45.
4. Lindqvist E, Jonsson K, Saxne T, Eberhardt K,. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 611-6.
5. Stastny P,. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976; 57: 1148-57.
6. Gregersen PK, Silver J, Winchester RJ,. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
7. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52: 3433-8.
8. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005; 52: 3058-62.
9. Jawaheer D, Li W, Graham RR, Chen W, Damle A, Xiao X, et al. Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet 2002; 71: 585-94.
10. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44: 291-6.
11. Han B, Diogo D, Eyre S, Kallberg H, Zhernakova A, Bowes J, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet 2014; 94: 522-32.
12. Kast WM, de Waal LP, Melief CJ,. Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells. J Exp Med 1984; 160: 1752-66.
13. Schumacher TN, Van Bleek GM, Heemels MT, Deres K, Li KW, Imarai M, et al. Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules. Eur J Immunol 1992; 22: 1405-12.
14. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR,. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006; 54: 1117-21.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
17. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Rantapaa-Dahlqvist S,. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35: 1002-8.
18. Rodriguez-Rodriguez L, Jover-Jover J, Fontsere O, Pena-Blanco R, Leon L, Fernandez-Gutierrez B, et al. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand J Rheumatol 2013; 42: 433-6.
19. Wolfe F, Michaud K,. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) 2011; 50: 16-24.
20. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013; 8: e64683.
21. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-201.
22. Brown WM, Pierce J, Hilner JE, Perdue LH, Lohman K, Li L, et al. Overview of the MHC fine mapping data. Diabetes Obes Metab 2009; 11: 2-7.
23. Reviron D, Perdriger A, Toussirot E, Wendling D, Balandraud N, Guis S, et al. Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum 2001; 44: 535-40.
24. De Vries N, Tijssen H, van Riel PL, van de Putte LB,. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis Rheum 2002; 46: 921-8.
25. Knevel R, de Rooy DP, Zhernakova A, Grondal G, Krabben A, Steinsson K, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1684-93.
26. Knevel R, Tsonaka R, le Cessie S, van der Linden MP, Huizinga TW, van der Heijde DM, et al. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 2013; 42: 182-9.
27. Scally SW, Petersen J, Law SC, Dudek NL, Nel HJ, Loh KL, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013; 210: 2569-82.